LivaNova to Restructure its Heart Valve Business Line and End Caisson Transcatheter Mitral Valve Replacement Program
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it is ending its Caisson Transcatheter Mitral Valve Replacement (TMVR) program and will undertake a restructuring of its heart valve business to improve profitability and ensure business continuity.
“The time has come to address the continued declines we have experienced in our heart valve business. We will restructure and simplify our heart valve manufacturing network, which will eliminate operational overlap between facilities and enable us to address new regulatory requirements,” said Damien McDonald, Chief Executive Officer of LivaNova. “As we evaluated these changes along with those in the structural heart market, we determined it was no longer viable to continue to invest in our TMVR program. As a result, we will close our Caisson TMVR operations.”
The LivaNova heart valve business line represented nearly $130 million in revenue for full-year 2018 and has experienced a revenue decline over the last five years across both biological and mechanical valves. These declines were due to multiple market conditions, while portfolio maintenance costs increased specifically due to higher regulatory requirements. After a comprehensive analysis, the Company determined a restructuring is necessary.
Under this plan, LivaNova’s Saluggia, Italy facility will become dedicated to R&D and production of mechanical heart valves, rings, accessories and Nitinol stents. LivaNova tissue heart valve production will be concentrated in the Company’s Vancouver, Canada plant.
The closure of Caisson TMVR operations in Minneapolis, Minn. will be effective at the end of 2019. Patients who participated in clinical trials related to TMVR will continue to be followed within the parameters of the trial.
Under the restructuring plan, which will be implemented subject to any prior information and consultation procedure with social parties according to local legislation, it is expected that approximately 150 employees can be potentially impacted in the three sites of Saluggia, Vancouver and Minneapolis.
LivaNova PLC is a global medical technology and innovation company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through innovative medical technologies, delivering life-changing improvements for both the Head and Heart. Headquartered in London, LivaNova employs approximately 4,000 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals and healthcare systems worldwide. LivaNova operates as two businesses: Cardiovascular and Neuromodulation, with operating headquarters in Mirandola (Italy) and Houston (U.S.), respectively.
For more information, please visit www.livanova.com.
Safe Harbor Statement
This news release contains forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements are not historical facts but are based on certain assumptions of management and describe LivaNova’s future plans, strategies and expectations. Forward-looking statements can generally be identified by the use of forward-looking terminology, including, but not limited to, "may," “could,” “seek,” “guidance,” “predict,” “potential,” “likely,” "believe," "will," "expect," "anticipate," "estimate," "plan," "intend," "forecast," or variations of these terms and similar expressions, or the negative of these terms or similar expressions. Forward-looking statements contained in this news release are based on information presently available to LivaNova and assumptions that LivaNova believes to be reasonable, but are inherently uncertain. As a result, LivaNova’s actual results, performance or achievements may differ materially from those expressed or implied by these forward-looking statements, which are not guarantees of future performance or actions that may be taken by LivaNova and involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond LivaNova’s control. You should carefully consider the risks and uncertainties that affect LivaNova, including those described in the “Risk Factors” section of LivaNova’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other documents filed from time to time with the United States Securities and Exchange Commission.
All information in this news release is as of the date of its release. LivaNova does not undertake or assume any obligation to update publicly any of the forward-looking statements in this news release to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. We caution you not to place undue reliance on any forward-looking statements, which are made only as of the date of this news release.
LivaNova PLC Investor Relations and Media
Melissa Farina, +1 (281) 228-7262
Vice President, Investor Relations
Deanna Wilke, +1 (281) 727-2764
Director, Corporate Communications
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Allegro DVT Extends Leadership in 8K Video Decoding IP1.10.2020 11:00:00 EEST | Press release
Allegro DVT, the leading provider of video semiconductor IP and video compliance streams, today announced the release of its AL-D3x0 family of multi-format 8K60 video decoder IPs. This complete family of multi-format video decoder IP cores enables customers to support video decoding at rates of up to 8K60 and beyond in a compact implementation optimized to a wide range of end market applications. As video applications shift from 4K to 8K, the industry needs power and cost efficient decoding cores to enable rapid rollout of new generation of devices and solutions capable of supporting such super high resolutions. With the AL-D3x0 family of products, Allegro is able to address this growing demand by providing highly configurable decoding IP core supporting a variety of selectable codecs such as JPEG, H.264, HEVC, VP9 and AV1. Furthermore, Allegro DVT’s unique and scalable architecture approach offers the best trade-off between silicon size and power consumption and keeps the operating fr
Avanti Acquisition Corp. Announces Launch of $500,000,000 Initial Public Offering1.10.2020 10:00:00 EEST | Press release
Avanti Acquisition Corp. (the “Company”), a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, today announced the commencement of its initial public offering of 50,000,000 units at a price of $10.00 per unit. The Company is sponsored by Avanti Acquisition SCSp, an affiliate of NNS Group, the private family office of Nassef Sawiris and Sienna Capital, a subsidiary of Groupe Bruxelles Lambert. The Company intends to be sector agnostic and to focus on European family owned or founder led businesses with a US nexus. The units are expected to be listed on the New York Stock Exchange (the “NYSE”) and trade under the ticker symbol “AVAN.U”. Each unit consists of one share of Class A common stock and one-half of one redeemable warrant. Each whole warrant may be exercised for one share of Class A common stock at a price of $11.50 per share. Only
Castles Technology Announces the Acquisition of Spire Payments1.10.2020 08:59:00 EEST | Press release
Castles Technology, one of the top global payment solutions providers which offers services to more than 50 countries around the globe, today announced completion of the acquisition of the business and assets of Spire Payments, the leading European based EFTPOS terminal solutions provider. With the acquisition of the business and assets of Spire Payments, Castles Technology is now even better positioned to deliver market-leading payment solutions that simplify and enhance merchants’ businesses, from in-store acceptance services to value-added solutions. Jean-Philippe Niedergang, Group CCO Castles Technology, says: “I am delighted to welcome Spire Payments’ customers and new colleagues to the Castles Technology family. This acquisition represents an important strategic move for the future of our businesses, as we continue to evolve and innovate to provide merchants acquirers with future-forward payments solutions.” “This acquisition delivers a perfect match between the two companies, wi
BIOCORP Announces Partnership with AARDEX Group to Extend Smart Solutions for Precision Medication Adherence1.10.2020 08:30:00 EEST | Press release
Regulatory News: BIOCORP (Paris:ALCOR) (FR0012788065 - ALCOR / Eligible PEA PME), a French company specialized in the design, development and manufacture of innovative medical devices, today announced an alliance with Belgium-based AARDEX Group, the world leader in medication adherence solutions. This alliance is to combine BIOCORP’s connected add-on solutions for drug delivery devices with AARDEX’s proprietary Medication Event Monitoring System (MEMS®) and offer a comprehensive solution to patients and healthcare providers to effectively measure and manage medication adherence. The financial terms of the agreement have not been disclosed, however the first initiative will be to integrate BIOCORP’s Injay connected solution for Pre-filled syringes (PFS) to AARDEX’s MEMS Adherence Software (MEMS AS®), to target medicines delivered by PFS with potential applications in the field of Rheumatoid Arthritis, Multiple Sclerosis, Ophthalmology, Psoriasis or Cardiovascular diseases. The roadmap a
JEOL Strengthens European Business in the Medical Equipment Segment1.10.2020 03:30:00 EEST | Press release
JEOL Ltd. (TOKYO:6951) (President & COO Izumi Oi) has opened a new facility in JEOL (EUROPE) B.V. (Zaventem, Belgium) on October 1, 2020, aiming to strengthen the Medical Equipment business in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200930006021/en/ Demo site JEOL (EUROPE) B.V. (Photo: Business Wire) This foundation, with three instruments in operation, not only offers customers the possibility of practical demonstrations and intensive service / application training, but also enables high-quality service and fast logistics from the dedicated warehouse. This new approach is based on a long-term plan that whilst keeping pace with a high standard and matured medical environment in Europe, we will also cover emerging regions such as the Middle East, Eastern Europe and Russia, where the expected growth in economy and population can lead to a steady demand for medical infrastructure. We will continue to promote over
International AI Art Competition Enters Final Round30.9.2020 19:16:00 EEST | Press release
Ten finalists have been announced for AI Artathon, the first ever international AI Art competition held in Saudi Arabia. The finalists were revealed during a livestream event to showcase artworks created by the competitors using artificial intelligence tools and techniques. The three winning teams will be announced at the Global AI Summit on 22nd October, where they will share a prize of US$133,000. The AI Artathon is an initiative of the Global AI Summit, to highlight the creative potential of humans and machines working together to create innovative artworks. Twenty teams made up of artists, graphic designers, AI experts and programmers, competed in this stage of the competition, after qualifying during a hackathon held in Riyadh in January. Over 2,000 people from over 50 countries applied to participate in the hackathon, with 300 selected for the three-day event, where teams were formed to develop initial AI art concepts. Twenty teams were selected to take part in a bootcamp, where
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom